Lifestyle

Why Mezion Pharma Co., Ltd. Sold Its Australian Patent for 5.4 Billion… Reduces ‘Legal Losses by 75%’ to Avoid Being Designated a ‘Watch List’ Stock

KIM JI-WAN
2026-11-17 06:01:02
[Edaily Reporter KIM JI-WAN ] Mezzion Pharma Co., Ltd.(140410)has taken a calculated risk by selling two Australian patents for udenafil for 5.4 billion won, thereby removing itself from the list of stocks subject to investment caution and reducing the risk of being designated as a managed stock.

Mezzion Pharma Co., Ltd.’s website. (Screenshot by ReporterKIM JI-WAN )


Mezzion Pharma Co., Ltd. announced on the 4th that it had signed an agreement with Hepaguard International to transfer the Australian patent rights for Udenafil. Under the terms of the agreement, the two Australian patents for Udenafil will be sold for $4 million (approximately 5.4 billion won).

The patents included in this transaction cover: △ a treatment method for improving patients’ heart muscle function; and △ a method for improving exercise capacity and cardiac function in patients with single-ventricle heart disease. Hepaguard will assume full ownership of both patents in Australia. Payment will be made in two installments: $2 million by December 31 of this year, and the remaining $2 million by February 28 of next year.

Mezzion Pharma Co., Ltd. aims to address two key issues through this patent transfer.

First is the five consecutive years of operating losses that led to the company being labeled an “Investment Caution Stock.” In March, the Korea Exchange designated Mezion Pharma Co., Ltd. as an Investment Caution Stock due to five consecutive fiscal years of operating losses. The company plans to reflect the profits from this patent transfer in its operating results to end its streak of consecutive losses.

Second is the ratio of losses from continuing operations before income tax to equity, which soared to 75.4% last year. On the KOSDAQ, a company is designated as a “monitored stock” if, in two out of the three most recent fiscal years (including the current one), losses from continuing operations before income tax exceed 1 billion won each year and surpass 50% of equity.

In 2024, Mezion Pharma Co., Ltd.’s loss from continuing operations amounted to approximately 14.5 billion won, representing just 31.5% of its equity of 46.1 billion won. Last year, the adjusted loss from continuing operations—calculated by excluding approximately 25.9 billion won in valuation losses on derivatives related to convertible bonds from the reported loss of 38.8 billion won—was approximately 12.9 billion won. This represented a decrease of 1.6 billion won from the previous year. However, as equity shrank to 17.2 billion won due to accumulated losses, the statutory loss ratio jumped to 75.4%.

As a result, Mezion Pharma Co., Ltd. exceeded the statutory loss threshold last year, as the ratio surpassed 50% of its equity. If Mezion Pharma Co., Ltd.’s ratio exceeds 50% again this year, it will be grounds for designation as a “monitored stock.”

This was the rationale behind Mezion Pharma Co., Ltd.’s issuance of 36.5 billion won in convertible bonds last April, as the company weighed the cash needed to complete clinical trials, the projected statutory loss, and the scale of capital expansion. Even if clinical trial costs are covered by the convertible bonds, the funds raised do not automatically translate into operating profit. This time, the company opted to monetize its Australian patent to reduce the annual loss itself.

Park Dong-hyun, CEO of Mezion Pharma Co., Ltd. (Photo: ReporterKIM JI-WAN )


Park Dong-hyun, Chairman of Mezion Pharma Co., Ltd., stated, “We are making the removal of the ‘Investor Caution’ designation our top priority,” adding, “Among various options, we decided to pursue the ‘patent transfer’ plan, which is the most realistic and can be implemented at an early stage.”

Chairman Park continued, “We will completely resolve the accounting issues that have been holding the company back by the end of this year,” adding, “We will refocus all our capabilities on our core mission of enhancing shareholder value and developing new drugs.”

Meanwhile, while Mezion Pharma Co., Ltd. is selling its rights in Australia, the global Phase 3 clinical trial for Udenafil, “FUEL-2,” has expanded its scope to Europe. Following the United States and South Korea, patient recruitment began on the 1st of last month at Great Ormond Street Hospital for Children in London, England. The company plans to recruit patients from 14 hospitals across six European countries, including the United Kingdom, France, Italy, Germany, the Netherlands, and Slovakia.

Economy

Corporation

IT·Science

Economy

[37th SRE][Cover] The Paradox of the Semiconductor Boom… Whether Prices Rise or Fall, the Credit “Time Bomb” Remains

Semiconductors were the driving force behind the Korean economy this year. With exports rebounding thanks to a memory chip boom fueled by artificial intelligence (AI), growth is expected to reach the …
2026-11-17 06:00:08

Corporation

Why Mezion Pharma Co., Ltd. Sold Its Australian Patent for 5.4 Billion… Reduces ‘Legal Losses by 75%’ to Avoid Being Designated a ‘Watch List’ Stock

Mezzion Pharma Co., Ltd.(140410)has taken a calculated risk by selling two Australian patents for udenafil for 5.4 billion won, thereby removing itself from the list of stocks subject to investment ca…
2026-11-17 06:01:02

IT·Science

Rainbow Robotics Reports 3Q Revenue of 13.9 Billion Won… Loss Widens

Rainbow Robotics(277810)reported a widening net loss in the third quarter of this year despite revenue growth. While sales to its largest shareholder, SamsungElectronics, increased, the proportion of …
2026-11-16 18:49:08